Novo Nordisk A/S (NYSE:NVO) Shares Acquired by Gilliland Jeter Wealth Management LLC

Gilliland Jeter Wealth Management LLC lifted its position in Novo Nordisk A/S (NYSE:NVO) by 416.7% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 930 shares of the company’s stock after acquiring an additional 750 shares during the period. Gilliland Jeter Wealth Management LLC’s holdings in Novo Nordisk A/S were worth $111,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently made changes to their positions in the company. First PREMIER Bank purchased a new position in shares of Novo Nordisk A/S during the 1st quarter worth $25,000. 1620 Investment Advisors Inc. purchased a new stake in shares of Novo Nordisk A/S during the 2nd quarter worth approximately $25,000. Strategic Investment Solutions Inc. IL acquired a new stake in shares of Novo Nordisk A/S during the second quarter worth about $25,000. Dixon Mitchell Investment Counsel Inc. purchased a new stake in Novo Nordisk A/S in the first quarter valued at approximately $26,000. Finally, Orion Capital Management LLC purchased a new position in Novo Nordisk A/S during the 1st quarter worth $26,000. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Novo Nordisk A/S Stock Performance

Shares of NVO stock opened at $118.09 on Monday. The company has a debt-to-equity ratio of 0.46, a current ratio of 0.94 and a quick ratio of 0.75. The company’s fifty day moving average price is $128.48 and its two-hundred day moving average price is $131.72. The firm has a market capitalization of $529.93 billion, a P/E ratio of 40.44, a P/E/G ratio of 1.56 and a beta of 0.42. Novo Nordisk A/S has a 12 month low of $92.94 and a 12 month high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Wednesday, August 7th. The company reported $0.65 earnings per share for the quarter, missing analysts’ consensus estimates of $0.71 by ($0.06). The business had revenue of $9.82 billion for the quarter, compared to analyst estimates of $9.91 billion. Novo Nordisk A/S had a return on equity of 87.43% and a net margin of 34.86%. On average, research analysts anticipate that Novo Nordisk A/S will post 3.01 earnings per share for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The business also recently disclosed a semi-annual dividend, which was paid on Monday, August 26th. Investors of record on Friday, August 16th were issued a $0.5126 dividend. This represents a yield of 0.7%. The ex-dividend date of this dividend was Friday, August 16th. Novo Nordisk A/S’s payout ratio is currently 24.66%.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on NVO. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Thursday, October 10th. BMO Capital Markets decreased their target price on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a research report on Thursday. Finally, StockNews.com downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 9th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $144.50.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.